On June 30, 2025 Laverock Therapeutics, a gene control company powering the development of disease-responsive advanced therapies, reported the expansion of its seed funding round, taking the total raised to more than £20m. The investment was led by Calculus Capital, with participation from existing investors Eli Lilly and Company, Mercia Ventures, Eos Advisory and MavenCapital Partners. The company also welcomed new investor, Norcliffe Capital.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This additional investment marks a transformational period for Laverock. The company has achieved platform development and validation and is transitioning to lead product selection, reporting positive functional data for both its primary T-cell and Macrophage programmes, demonstrating enhanced tumour control in haematological and solid tumour cancer models. Laverock’s unique platform technologies provide the potential to transform the efficacy, precision and safety of advanced therapies, through implementation of its programmable, tunable and multiplex gene silencing approach.
Elizabeth Klein, Investment Director at Calculus, said: "We are delighted to continue our support for Laverock’s progress in pioneering a new era of programmable advanced therapies. This new data and expanded funding demonstrate the potential of Laverock’s technologies. We look forward to continuing our work with David and the team as they drive forward product development opportunities, as well as delivering value for our investors."
David Venables, CEO of Laverock, added: "The Laverock team has been busy over recent months, continuing to validate our technology platforms but also generating functional data for our therapeutic programmes.This new funding will enable us to continue this development, as well as forming partnerships and collaborations to integrate our technologies into partners’ therapeutic pipelines. I’d like to thank all our existing and new investors for their continued support."
To reflect Laverock’s recent progress, the company has updated its corporate identity, including the launch of a new website, to demonstrate the expansion of its platform technologies and facilitate an enhanced focus on partnering and outlicensing activities.
(Press release, Laverock Therapeutics, JUN 30, 2025, View Source [SID1234668713])